A Phase 3 interventional study of MEDI4736 and MEDI4736 + Tremelimumab in Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN, sponsored by AstraZeneca. Completed at 169 sites in 24 countries. Open to participants aged 18 Years to 96 Years. Per ClinicalTrials.gov, last updated 2021-02-10.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Head and Neck Neoplasms by AstraZeneca — 1 open to participants now, 3 under way, 1 of them phase 3. Head and Neck Neoplasms · AstraZeneca.
Among the 17 studies in Head and Neck Neoplasms by AstraZeneca, this one has the largest enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2015, is one of 2 in phase 3, and was the 12th registered.
2,714 studies on the registry are indexed under Head and Neck Neoplasms; 596 are open to participants now.
Browse Head and Neck Neoplasms studies →1 of the 17 studies in Head and Neck Neoplasms by AstraZeneca is open now, in 1 country. Recruiting first, the newest first:
AstraZeneca · Sites in United States
Ages 18–130
By country, each count listing its studies:
Of the 453 Head and Neck Neoplasms studies recruiting now, 345 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 21 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 96 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 2
First in 2002; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 736 is above the median of 46 across 2,033 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 47 across the 15 interventional studies, 100 across the 1 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Head and Neck Neoplasms by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient population.
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient population.
The main objectives of the study are to:
Patients will undergo a screening assessment on their tumor tissue sample to determine PD-L1 expression per a pre-specified cut-off level. Patients with ≥25% of tumor cells with membrane staining will be considered PD-L1 positive while those with 0% to 24% of tumor cells with membrane staining will be considered PD-L1 negative. Based on the underlying PD-L1 status, patients will be randomized in a 1:1:1 ratio to receive treatment with MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy, or SoC therapy. Patients who discontinue treatment in 1 treatment group may not switch to treatment in a different group.
Stratification factors include PD-L1 status, human papillomavirus status, (in patients with oropharyngeal cancer only), and smoking status.
Tumor assessments will be performed every 8 weeks until objective tumor response by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
2,714 studies on the registry are indexed under Head and Neck Neoplasms; 596 are open to participants now.
This study's enrollment of 736 is above the median of 46 across 2,033 interventional studies indexed under Head and Neck Neoplasms.
Browse Head and Neck Neoplasms studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Compared within Head and Neck Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: - Age ≥18 years; - Written obtained from the patient/legal representative; - or cytologically confirmed recurrent or SCCHN; - Tumor progression or recurrence during or after only one palliative systemic treatment regimen for recurrent or metastatic disease that must have contained a platinum agent OR progression within 6 months of the last dose of platinum given as part of multimodality therapy with curative intent; - Confirmed -positive or -negative SCCHN by the Ventana PD-L1 SP263 IHC assay; - WHO/ (ECOG) performance status of 0 or 1; At least 1 , - Not previously irradiated; - No prior exposure to immune-mediated therapy; - Adequate organ and marrow function; Evidence of status or negative urinary or serum pregnancy test for female pre-menopausal patients. Exclusion Criteria: - Histologically or cytologically confirmed squamous cell carcinoma of any other primary anatomic location in the head and neck; - Received more than 1 palliative systemic regimen for recurrent or metastatic disease; -Any concurrent chemotherapy, Product, biologic, or hormonal therapy for cancer treatment; - Receipt of any investigational anticancer therapy within 28 days or 5 half-lives; - Receipt of last dose of an approved (marketed) anticancer therapy (chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the first dose of study treatment; - Major surgical procedure within 28 days prior to the first dose of Investigational Product; - Any unresolved toxicity Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criterion; - Current or prior use of medication within 14 days before the first dose of their assigned Investigational Product; - History of allogeneic organ transplantation; - Active or prior documented or inflammatory disorders; - Uncontrolled intercurrent illness; - Patients with a history of , spinal cord compression, or ; - Mean corrected for heart rate (QTc) ≥470 ms calculated from 3 (ECGs) using Fridericia's Correction; - History of active primary immunodeficiency; - Active tuberculosis; - Active infection including , or (HIV); - Receipt of live, attenuated vaccine within 30 days prior to the first dose of Investigational Product; - Pregnant or breast-feeding female patients; - Known allergy or to Investigational Product
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MEDI4736 monotherapy
Drug: MEDI4736
MEDI4736 + tremelimumab combination therapy
Drug: MEDI4736 + Tremelimumab
Standard of Care
Drug: Standard of Care
MEDI4736 Monotherapy
Drug pages: Durvalumab · Tremelimumab
MEDI4736 + Tremelimumab combination therapy
Standard of Care
Overall Survival (OS)
OS is defined as the time from the date of randomization until death due to any cause. OS was analyzed for the full analysis set, regardless of programmed death-ligand 1 (PD-L1) status.
Time frame: September 2015 to September 2018 (36 months)
Overall Survival (OS) in PD-L1 Negative Participants
OS is defined as the time from the date of randomization until death due to any cause. PD-L1 negative was defined as \<25% of tumor cells with membrane staining for PD-L1 at any intensity.
Time frame: September 2015 to September 2018 (36 months)
Overall Survival (OS) in PD-L1 Positive Participants
OS is defined as the time from the date of randomization until death due to any cause. PD-L1 positive was defined as ≥25% of tumor cells with membrane staining for PD-L1 at any intensity.
Time frame: September 2015 to September 2018 (36 months)
Progression Free Survival (PFS)
PFS was defined as the time from the date of randomization until the date of objective disease progression or death based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). Objective disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: September 2015 to September 2018 (36 months)
Objective Response Rate (ORR)
The percentage of participants who experienced an objective response (complete response \[CR\] or partial response \[PR\]), based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.
Time frame: Assessed at randomization and every 8 weeks thereafter
Duration of Response (DoR)
Median DoR, in months, based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A complete response was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A partial response was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.
Time frame: September 2015 to September 2018 (36 months)
Disease Control Rate (DCR)
6 Months: The percentage of participants who had a best objective response of complete response (CR) or partial response (PR) in the first 6 months or had demonstrated stable disease (SD) for a minimum interval of 24 weeks following randomization. 12 Months: The percentage of participants who had a best objective response of CR or PR within 12 months or had demonstrated SD for a minimum interval of 48 weeks following randomization. Objective response was based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.
Time frame: Baseline up to 6 months; baseline up to 12 months
Percentage of Participants Alive and Progression Free (APF)
APF is defined as the percentage of participants who are alive and progression free at 6 months and 12 months after randomization. Estimates of progression free survival were based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). Objective disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Baseline up to 6 months; baseline up to 12 months
Percentage of Participants Alive
Percentage of participants alive at 12, 18 and 24 months using a Kaplan Meier estimate.
Time frame: 12, 18 and 24 months
Progression Free Survival (PFS) in PD-L1 Negative Participants
Number of participants with confirmed objective disease progression (PD) at the time of the participant's last evaluable response evaluation criteria in solid tumors 1.1 (RECIST1.1) assessment. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PD-L1 negative was defined as \<25% of tumor cells with membrane staining for PD-L1 at any intensity.
Time frame: September 2015 to September 2018 (36 months)
Objective Response Rate (ORR) in PD-L1 Negative Participants
The percentage of PD-L1 negative participants who experienced an objective response (complete response \[CR\] or partial response \[PR\]), based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters. PD-L1 negative was defined as \<25% of tumor cells with membrane staining for PD-L1 at any intensity.
Time frame: September 2015 to September 2018 (36 months)
Time to Deterioration in European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire, Version 3 (EORTC QLQ-C30)
The EORTC QLQ-C30 consists of 30 questions that can be combined to produce functional scales (e.g. physical), symptom scales (e.g. fatigue), and a global measure of health status. Each of the scales are measured from 0 to 100. Deterioration was defined as a 10-point decrease from baseline in a functioning or global health status/ quality of life score or a 10-point increase from baseline in a symptom score.
Time frame: September 2015 to September 2018 (36 months)
Time to Deterioration for European Organisation for Research and Treatment of Cancer 35-item Head and Neck Quality of Life Questionnaire (EORTC QLQ-H&N35)
The EORTC QLQ-H\&N35 comprises of 35 questions to assess head and neck cancer symptoms (e.g. pain, swallowing). Deterioration was defined as a 10-point increase from baseline in the symptom score.
Time frame: September 2015 to September 2018 (36 months)
Number of Participants Reporting One or More Adverse Events (AE)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Inclusive of AEs and serious AEs.
Time frame: First dose to last dose + 90 days or data cut off (up to 36 months)
| Milestone | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| Started | 247 | 240 | 249 |
| Received treatment | 246 | 237 | 240 |
| Completed | 203 | 183 | 188 |
| Not completed | 44 | 57 | 61 |
| Withdrew: Lost to follow-up | 2 | 2 | 2 |
| Withdrew: Withdrawal by subject | 7 | 9 | 27 |
| Withdrew: Miscellaneous | 1 | 1 | 0 |
| Withdrew: On treatment/off study | 34 | 45 | 32 |
OS is defined as the time from the date of randomization until death due to any cause. OS was analyzed for the full analysis set, regardless of programmed death-ligand 1 (PD-L1) status.
| Months | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| Overall Survival (OS) | 6.5 (5.5 to 8.2) | 7.6 (6.1 to 9.8) | 8.3 (7.3 to 9.2) |
OS is defined as the time from the date of randomization until death due to any cause. PD-L1 negative was defined as \<25% of tumor cells with membrane staining for PD-L1 at any intensity.
| Months | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| Overall Survival (OS) in PD-L1 Negative Participants | 7.8 (5.9 to 10.3) | 7.6 (6.2 to 9.5) | 8.0 (6.7 to 8.9) |
OS is defined as the time from the date of randomization until death due to any cause. PD-L1 positive was defined as ≥25% of tumor cells with membrane staining for PD-L1 at any intensity.
| Months | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| Overall Survival (OS) in PD-L1 Positive Participants | 4.8 (3.3 to 6.4) | 9.8 (4.3 to 14.1) | 9.0 (6.8 to 9.2) |
PFS was defined as the time from the date of randomization until the date of objective disease progression or death based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). Objective disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| Months | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| Progression Free Survival (PFS) | 2.0 (1.9 to 2.3) | 2.1 (1.9 to 3.0) | 3.7 (3.1 to 3.7) |
The percentage of participants who experienced an objective response (complete response \[CR\] or partial response \[PR\]), based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.
| Percentage of participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| Objective Response Rate (ORR) | 18.2 (13.6 to 23.6) | 17.9 (13.3 to 23.4) | 17.3 (12.8 to 22.5) |
Median DoR, in months, based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A complete response was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A partial response was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.
| Months | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| Duration of Response (DoR) | 7.4 (2.8 to NA) | 12.9 (5.6 to NA) | 3.7 (1.9 to 5.5) |
6 Months: The percentage of participants who had a best objective response of complete response (CR) or partial response (PR) in the first 6 months or had demonstrated stable disease (SD) for a minimum interval of 24 weeks following randomization. 12 Months: The percentage of participants who had a best objective response of CR or PR within 12 months or had demonstrated SD for a minimum interval of 48 weeks following randomization. Objective response was based on investigator assessments, according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.
| Percentage of participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| 6 Months | 25.1 | 24.2 | 24.9 |
| 12 Months | 20.6 | 18.8 | 18.9 |
APF is defined as the percentage of participants who are alive and progression free at 6 months and 12 months after randomization. Estimates of progression free survival were based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). Objective disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| Percentage of participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| 6 Months | 22.5 (17.4 to 28.0) | 25.1 (19.7 to 30.9) | 23.3 (17.8 to 29.3) |
| 12 Months | 11.0 (7.4 to 15.5) | 14.4 (10.1 to 19.5) | 5.7 (2.8 to 10.2) |
Percentage of participants alive at 12, 18 and 24 months using a Kaplan Meier estimate.
| Percentage of participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| 12 Months | 30.4 (24.7 to 36.3) | 37.0 (30.9 to 43.1) | 30.5 (24.7 to 36.4) |
| 18 Months | 21.0 (15.9 to 26.5) | 25.4 (19.9 to 31.3) | 17.8 (13.1 to 23.2) |
| 24 Months | 13.3 (8.9 to 18.6) | 18.4 (13.3 to 24.1) | 10.3 (5.7 to 16.5) |
Number of participants with confirmed objective disease progression (PD) at the time of the participant's last evaluable response evaluation criteria in solid tumors 1.1 (RECIST1.1) assessment. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PD-L1 negative was defined as \<25% of tumor cells with membrane staining for PD-L1 at any intensity.
| Participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| Progression Free Survival (PFS) in PD-L1 Negative Participants | 154 | 151 | 144 |
The percentage of PD-L1 negative participants who experienced an objective response (complete response \[CR\] or partial response \[PR\]), based on investigator assessments according to response evaluation criteria in solid tumors 1.1 (RECIST1.1). A CR was defined as the disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. A PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters. PD-L1 negative was defined as \<25% of tumor cells with membrane staining for PD-L1 at any intensity.
| Percentage of participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| Objective Response Rate (ORR) in PD-L1 Negative Participants | 17.7 (12.4 to 24.2) | 14.0 (9.1 to 20.0) | 15.3 (10.3 to 21.4) |
The EORTC QLQ-C30 consists of 30 questions that can be combined to produce functional scales (e.g. physical), symptom scales (e.g. fatigue), and a global measure of health status. Each of the scales are measured from 0 to 100. Deterioration was defined as a 10-point decrease from baseline in a functioning or global health status/ quality of life score or a 10-point increase from baseline in a symptom score.
| Months | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| Function - Physical | 2.0 (1.9 to 3.2) | 2.2 (1.9 to 3.5) | 3.7 (2.3 to 4.6) |
| Symptom - Fatigue | 1.8 (1.3 to 1.9) | 1.4 (1.0 to 1.9) | 1.9 (1.6 to 2.6) |
| Global health status/QoL | 1.9 (1.8 to 2.7) | 2.8 (1.9 to 3.8) | 3.5 (2.9 to 4.0) |
The EORTC QLQ-H\&N35 comprises of 35 questions to assess head and neck cancer symptoms (e.g. pain, swallowing). Deterioration was defined as a 10-point increase from baseline in the symptom score.
| Months | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| Pain (Mouth/ Throat) | 2.9 (2.4 to 3.8) | 2.8 (2.6 to 3.7) | 3.4 (2.7 to 4.0) |
| Swallowing | 2.6 (1.9 to 3.6) | 2.8 (1.9 to 3.9) | 3.7 (2.9 to 4.6) |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Inclusive of AEs and serious AEs.
| Participants | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| Number of Participants Reporting One or More Adverse Events (AE) | 232 | 214 | 229 |
Collected over First dose to last dose + 90 days or data cut off (maximum exposure 32 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Durvalumab + Tremelimumab | 206/247 (83.4%) | 79/246 (32.1%) | 203/246 (82.5%) |
| Durvalumab | 186/240 (77.5%) | 69/237 (29.1%) | 180/237 (75.9%) |
| Standard of Care (SoC) | 199/249 (79.9%) | 61/240 (25.4%) | 207/240 (86.3%) |
| Event | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| PneumoniaInfections and infestations | 9/246 | 8/237 | 9/240 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 7/246 | 4/237 | 2/240 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 3/246 | 5/237 | 2/240 |
| AnaemiaBlood and lymphatic system disorders | 5/246 | 0/237 | 1/240 |
| General physical health deteriorationGeneral disorders | 0/246 | 4/237 | 1/240 |
| HypercalcaemiaMetabolism and nutrition disorders | 2/246 | 4/237 | 2/240 |
| SepsisInfections and infestations | 3/246 | 0/237 | 4/240 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/246 | 1/237 | 0/240 |
| DysphagiaGastrointestinal disorders | 4/246 | 1/237 | 1/240 |
| PyrexiaGeneral disorders | 4/246 | 2/237 | 2/240 |
| Event | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 55/246 | 47/237 | 56/240 |
| AstheniaGeneral disorders | 51/246 | 42/237 | 56/240 |
| Decreased appetiteMetabolism and nutrition disorders | 44/246 | 30/237 | 48/240 |
| NauseaGastrointestinal disorders | 30/246 | 27/237 | 41/240 |
| FatigueGeneral disorders | 40/246 | 31/237 | 35/240 |
| DiarrhoeaGastrointestinal disorders | 38/246 | 24/237 | 32/240 |
| RashSkin and subcutaneous tissue disorders | 18/246 | 19/237 | 36/240 |
| HypothyroidismEndocrine disorders | 32/246 | 33/237 | 5/240 |
| ConstipationGastrointestinal disorders | 33/246 | 33/237 | 29/240 |
| NeutropeniaBlood and lymphatic system disorders | 11/246 | 4/237 | 32/240 |
| Age, Continuous(Years) | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) | Total |
|---|---|---|---|---|
| Mean | 59.9 ± 9.14 | 59.0 ± 10.07 | 59.5 ± 10.37 | 59.4 ± 9.86 |
| Age, Customized(Participants) | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) | Total |
|---|---|---|---|---|
| < 65 Years | 174 | 169 | 171 | 514 |
| >= 65 - < 75 Years | 63 | 56 | 64 | 183 |
| >= 75 Years | 10 | 15 | 14 | 39 |
| Sex: Female, Male(Participants) | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) | Total |
|---|---|---|---|---|
| Female | 38 | 38 | 42 | 118 |
| Male | 209 | 202 | 207 | 618 |
| Ethnicity (NIH/OMB)(Participants) | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 16 | 15 | 13 | 44 |
| Not Hispanic or Latino | 226 | 223 | 229 | 678 |
| Unknown or Not Reported | 5 | 2 | 7 | 14 |
| Race/Ethnicity, Customized(Participants) | Durvalumab + Tremelimumab | Durvalumab | Standard of Care (SoC) | Total |
|---|---|---|---|---|
| Asian | 33 | 35 | 45 | 113 |
| Black Or African American | 1 | 0 | 3 | 4 |
| Other | 4 | 5 | 3 | 12 |
| White | 204 | 198 | 189 | 591 |
| Unknown or Not Reported | 5 | 2 | 9 | 16 |
Showing the first 100 of 169 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Sep 2015 to primary completion in Sep 2018, 36 months.
Results were first posted in Oct 2019, 1 year after primary completion.
Of 66 phase 3 interventional studies under Head and Neck Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 100. This study's 36 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Durvalumab · Tremelimumab